ANNUAL REPORT 06 - Bosnalijek dd

51% LIBIYA24% KUWAIT19% QATAR6% YEMENFirst sale of B osnalijek produc ts was realised in Yemen.Middle East and Africa RegionSale in this export region was doubled in relation to previous year.With significant growth of sale of 112% in relation to previous year, thisexport market represents a significant potential and the real results areexpected after finalising the commenced and new registrationprocedures and preparation of sale-marketing activities in certaincountries.Activities were especially directed to registration of products in sevenAfrican French- speaking countries as well as coordinating marketingactivities with partner in these countries. First registrations of 10products were finished in Congo and Togo, and their finalisation in othercountries as well is expected in year 2007.• A continuous sale has been realised in Kuwait and further registrationof medications continued.• At Qatar market, the sale was increased by 2.5 times, and registrationof 5 new products commenced.• The sale of Bosnalijek products in Libya was increased by 3.6 times inrelation to year 2005, and many activities were realised that aresupposed to result in Bosnalijek significant business successes in thecoming period.• Marketing authorisation approvals were obtained in Yemen for 7products and first sale in this country took place.Leading expor t produc tsTotal expor t in 2006 was accomplished with sale of 122 different produc ts in 14 countries.Lopril®H and Lysobac t® are leading B osnalijek produc ts at the value of expor t, whichbecame recognisable brands in many foreign markets, and they are followed by Nomigren®,Enterofur yl®, Stomatidin®, Lopril®, Ranibos® and Rhinostop®.serving Your health INTERNATIONAL MARKETS ANNUAL REPORT 06 29